The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins

International Journal of Oncology

Volumn 31, Issue 6, 2007, Pages 1465-1472

  Wakamatsu, Takahiro ^a   Nakahashi, Yoshitsugu ^a   Hachimine, Daisaku ^a   Seki, Toshihito ^a   Okazaki, Kazuichi ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Cisplatin; Glycyrrhizin; Hepatocellular carcinoma; Lamivudine; Multidrug resistance associated proteins

Indexed keywords

ABCB1 PROTEIN, HUMAN; ABCC5 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CISPLATIN; GLYCOPROTEIN P; GLYCYRRHIZIC ACID; LAMIVUDINE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG;

ARTICLE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MULTIDRUG RESISTANCE; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLYCYRRHIZIC ACID; HUMANS; LAMIVUDINE; LIVER NEOPLASMS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 38449088390     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.6.1465     Document Type: Article

References (57)

1. Llovet JM: Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.
2. Schafer DF and Sorrell MF: Hepatocellular carcinoma. Lancet 353: 1253-1257, 1999.
3. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, et al: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124, 1989.
4. Itsubo M, Ishikawa T, Toda G and Tanaka M: Immunohistochemical study of expression and cellular localization of the multidrug resistance gene product P-glycoprotein in primary liver carcinoma. Cancer 73: 298-303, 1994.
5. Lai EC, Choi TK, Cheng CH, Mok FP, Fan ST, Tan ES and Wong J: Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil. Cancer 66: 1685-1687, 1990.
6. Shen DW, Lu YG, Chin KV, Pastan I and Gottesman MM: Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression. J Cell Sci 98: 317-322, 1991.
7. Borst P, Evers R, Kool M and Wijnholds J: A family of drug transporters, the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295-1302, 2000.
8. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SP and Deeley RG: Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357-361, 1994.
9. Kruh GD and Belinsky MG: The MRP family of drug efflux pumps. Oncogene 22: 7537-7552, 2003.
10. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F and Borst P: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57: 3537-3547, 1997.
11. Kruh GD, Zeng H, Rea PA, Liu G, Chen ZS, Lee K and Belinsky MG: MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 33: 493-501, 2001.
12. Jedlitschky G, Leier I, Buchholz U, Hummel-Eisenbeiss J, Burchell B and Keppler D: ATP-dependent transport of bilirubin glucuronides by the multidrug resistance protein MRP1 and its hepatocyte canalicular isoform MRP2. Biochem J 327: 305-310, 1997.
13. Zeng H, Liu G, Rea PA and Kruh GD: Transport of amphipathic anion by human multidrug resistance protein 3. Cancer Res 60: 4779-4784, 2000.
14. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A and Fridland A: MRP4, a previously unidentified factor in drug resistance to nucleoside-based antiviral drugs. Nat Med 5: 1048-1051, 1999.
15. Wijnholds J, Mol CAAM, van Deemter L, de Haas M, Scheffer GL, Baas F, Beijnen JH, Scheper RJ, Hatse S, de Clercq E, Balzarini J and Borst P: Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci USA 97: 7476-7481, 2000.
16. Carr BI: Hepatocellular carcinoma, current management and future trends. Gastroenterology 127 (suppl 1): S218-S224, 2004.
17. Nishio K, Nakamura T, Koh Y, Suzuki T, Fukumoto H and Saijo N: Drug resistance in lung cancer. Curr Opin Oncol 11: 109-115, 1999.
18. Taniguchi K, Wada M, Kohno K, Nakamura T, Kawabe T, Kawakami M, Kagotani K, Okumura K, Akiyama S and Kuwano M: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res 56: 4124-4129, 1996.
19. Koike K, Kawabe T, Tanaka T, Toh S, Uchiumi T, Wada M, Akiyama S, Ono M and Kuwano M: A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 57: 5475-5479, 1997.
20. Savaraj N, Wu C, Wangpaichitr M, Kuo MT, Lampidis T, Robles C, Furst AJ and Feun L: Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: Collateral sensitivity to azidothymidine. Int J Oncol 23: 173-179, 2003.
21. Oguri T, Isobe T, Suzuki T, Nishio K, Fujiwara Y, Katoh O and Yamakido M: Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer. Int J Cancer 86: 95-100, 2000. (Pubitemid 30133993)
22. Matsushima Y and Baba T: An antigranulomatous effect of glycyrrhizin. J Exp Pathol 6: 25-30, 1992.
23. Ganem D and Prince AM: Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 350: 1118-1129, 2004.
24. Nakabayashi H, Taketa K, Yamane T, Miyazaki M, Miyano K and Sato J: Phenotypical stability of a human hepatoma cell line, Huh-7, in long-term culture with chemically defined medium. Gann 75: 151-158, 1984.
25. Sugimoto C, Fujieda S, Seki M, Sunaga H, Fan GK, Tsuzuki H, Borner C, Saito H and Matsukawa S: Apoptosis-promoting gene (bax) transfer potentiates sensitivity of squamous cell carcinoma to cisplatin in vitro and in vivo. Int J Cancer 82: 860-867, 1999.
26. Fields RD and Lancaster MV: Dual-attribute continuous monitoring of cell proliferation/cytotoxicity. Am Biotechnol Lab 11: 48-50, 1993.
27. Alcorn J, Lu X, Moscow JA and McNamara PJ: Transporter gene expression in lactating and nonlactating human mammary epithelial cells using real-time reverse transcription-polymerase chain reaction. J Pharmacol Exp Ther 303: 487-496, 2002.
28. Takeuchi A, Kaneko S, Matsushita E, Urabe T, Shimoda A and Kobayashi K: Interferon-alpha modulates resistance to cisplatin in three human hepatoma cell lines. J Gastroenterol 34: 351-358, 1999.
29. Pera MF Jr and Harder HC: Analysis for platinum in biological material by flameless atomic absorption spectrometry. Clin Chem 23: 1245-1249, 1977.
30. Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1535-1542, 1998.
31. Crul M, Schellens JH, Beijnen JH and Maliepaard M: Cisplatin resistance and DNA repair. Cancer Treat Rev 23: 341-366, 1997.
32. Gately DP and Howell SB: Cellular accumulation of the anticancer agent cisplatin: a review. Br J Cancer 67: 1171-1176, 1993.
33. Scala S, Pacelli R, Iaffaioli RV, Normanno N, Pepe S, Frasci G, Genua G, Tsuruo T, Tagliaferri P and Bianco AR: Reversal of adriamycin resistance by recombinant alpha-interferon in multidrug-resistant human colon carcinoma LoVo-doxorubicin cells. Cancer Res 51: 4898-4902, 1991.
34. Kang Y and Perry RR: Modulatory effects of tamoxifen and recombinant human alpha-interferon on doxorubicin resistance. Cancer Res 53: 3040-3045, 1993.
35. Chaudhary PM and Roninson IB: Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst 85: 632-639, 1993.
36. Guengerich FP: Metabolisn of chemical carcinogens. Carcinogenesis 21: 345-351, 2000.
37. Salinas AE and Wong MG: Glutathione S-transferases - a review. Curr Med Chem 6: 279-309, 1999.
38. Marie JP, Simonin G, Legrand O, Delmer A, Faussat AM, Lewis AD, Sikic BI and Zittoun R: Glutathione-S-transferases pi, alpha, mu and mdr1 mRNA expression in normal lymphocytes and chronic lymphocytic leukemia. Leukemia 9: 1742-1747, 1995.
39. Haga S, Hinoshita E, Ikezaki K, Fukui M, Scheffer GL, Uchiumi T and Kuwano M: Involvement of the multidrug resistance protein 3 in drug sensitivity and its expression in human glioma. Jpn J Cancer Res 92: 211-219, 2001.
40. Hirohashi T, Suzuki H and Sugiyama Y: Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (MRP3). J Biol Chem 274: 15181-15185, 1999.
41. Kool M, van der Linden M, de Haas M, Scheffer GL, de Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F and Borst P: MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc Natl Acad Sci USA 96: 6914-6919, 1999.
42. Faneyte IF, Kristel PM and van de Vijver MJ: Multidrug resistance associated genes MRP1, MRP2 and MRP3 in primary and anthracycline exposed breast cancer. Anticancer Res 24: 2931-2939, 2004.
43. Young LC, Campling BG, Voskoglou-Nomikos T, Cole SP, Deeley RG and Gerlach JH: Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res 5: 673-680, 1999.
44. Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G and Keppler D: Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38: 374-384, 2003.
45. Lee K, Belinsky MG, Bell DW, Testa JR and Kruh GD: Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. Cancer Res 58: 2741-2747, 1998.
46. Norris MD, Smith J, Tanabe K, Tobin P, Flemming C, Scheffer GL, Wielinga P, Cohn SL, London WB, Marshall GM, Allen JD and Haber M: Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol Cancer Ther 4: 547-553, 2005.
47. Maher JM, Cherrington NJ, Slitt AL and Klaassen CD: Tissue distribution and induction of the rat multidrug resistance-associated proteins 5 and 6. Life Sci 78: 2219-2225, 2006.
48. Pratt S, Shepard RL, Kandasamy RA, Johnston PA, Perry W III and Dantzig AH: The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Mol Cancer Ther 4: 855-863, 2005.
49. McAleer MA, Breen MA, White NL and Matthews N: pABC11 (also known as MOAT-C and MRP5), a member of the ABC family of proteins, has anion transporter activity but does not confer multidrug resistance when overexpressed in human embryonic kidney 293 cells. J Biol Chem 274: 23541-23548, 1999.
50. Suzuki T, Nishio K and Tanabe S: The MRP family and anticancer drug metabolism. Curr Drug Metab 2: 367-377, 2001.
51. Nies AT, Konig J, Cui Y, Brom M, Spring H and Keppler D: Expression of the multidrug resistance proteins MRP2 and MRP3 in human hepatocellular carcinoma. Int J Cancer 94: 492-499, 2001.
52. Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, Denk H and Trauner M: Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int 25: 367-379, 2005.
53. Dhiman RK and Chawla YK: Herbal medicines for liver diseases. Dig Dis Sci 50: 1807-1812, 2005.
54. Horikawa M, Kato Y, Tyson CA and Sugiyama Y: The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. Drug Metab Pharmacokinet 17: 23-33, 2002.
55. Thomas H, Foster G and Platis D: Mechanisms of action of interferon and nucleoside analogues. J Hepatol 39: S93-S98, 2003.
56. Conjeevaram HS and Lok AS: Management of chronic hepatitis B. J Hepatol 38 (suppl 1): S90-S103, 2003.
57. Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442, 2003.